Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | MLYCD | O95822 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5703500 | 0.89 | HPGD (0.73) | HPGDALDH1A1MAPTMLYCDLMNA | |
| SCHEMBL14817990 | 0.87 | HPGD (0.49) | HPGDALDH1A1MAPTMLYCDLMNA | |
| SCHEMBL10488234 | 0.84 | MLYCD (0.62) | HPGDALDH1A1MAPTMLYCDGAA | |
| SCHEMBL4405199 | 0.83 | MLYCD (0.68) | HPGDALDH1A1MAPTMLYCDLMNA | |
| SCHEMBL121475 | 0.81 | HPGD (0.66) | HPGDALDH1A1MAPTMLYCDLMNA | |
| SCHEMBL6802252 | 0.81 | HPGD (0.69) | HPGDALDH1A1MAPTMLYCDLMNA | |
| SCHEMBL1806308 | 0.81 | HPGD (0.63) | HPGDALDH1A1MAPTMLYCDLMNA | |
| SCHEMBL1018549 | 0.79 | HPGD (0.61) | HPGDALDH1A1MAPTMLYCDLMNA | |
| SCHEMBL3559829 | 0.79 | HPGD (0.61) | HPGDALDH1A1MAPTMLYCDLMNA | |
| SCHEMBL471629 | 0.79 | HPGD (0.61) | HPGDALDH1A1MAPTMLYCDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022169755-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| CN-103189373-B | The Triazolopyridine replaced | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-04-06 | — | — | CN | disclosed |
| CN-103608350-B | Triazolopyridine compounds | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-25 | — | — | CN | disclosed |
| CN-102753547-B | Triazolopyridine derivatives | BAYER IP GMBH | 2015-06-03 | — | — | CN | disclosed |
| EP-2133340-B1 | Novel benzazepine derivatives | GLAXO GROUP LTD (GB) | 2013-01-16 | — | — | EP | disclosed |
| EP-2186516-B1 | Novel benzazepine derivative | GLAXO GROUP LTD (GB) | 2013-01-16 | — | — | EP | disclosed |
| EP-2507236-A1 | TRIAZOLOPYRIDINE DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2012-10-10 | — | — | EP | disclosed |
| US-20120178763-A1 | Method of Treating Anxious Major Depressive Disorder | FREY JOSEPH (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178763-A1 | Method of Treating Anxious Major Depressive Disorder | FREY JOSEPH (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178763-A1 | Method of Treating Anxious Major Depressive Disorder | FREY JOSEPH (US) | 2012-07-12 | — | — | US | disclosed |
| WO-1994003451-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1994-02-17 | — | — | WO | disclosed |
| US-4990664-A | Drug for asthma or chronic bronchitis | GLAXO GROUP LIMITED (GB) | 1991-02-05 | — | — | US | disclosed |
| US-4990505-A | Treating asthma, bronchitis; adrenergic stimulants | GLAXO GROUP LIMITED (GB) | 1991-02-05 | — | — | US | disclosed |
| US-4853381-A | Ethanolamine compounds | GLAXO GROUP LIMITED (GB) | 1989-08-01 | — | — | US | disclosed |
| US-4853382-A | TREATING ASTHMA AND BRONCHITIS | GLAXO GROUP LIMITED (GB) | 1989-08-01 | — | — | US | disclosed |
| EP-0303466-A2 | Ethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 1989-02-15 | — | — | EP | disclosed |
| EP-0178919-B1 | AMINOPHENOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1988-12-21 | — | — | EP | disclosed |
| US-4730008-A | STIMULANT FOR BETA-ADRENORECEPTORS | GLAXO GROUP LIMITED (GB) | 1988-03-08 | — | — | US | disclosed |
| EP-0223410-A2 | Ethanolamine Derivatives | GLAXO GROUP LIMITED (GB) | 1987-05-27 | — | — | EP | disclosed |
| EP-0178919-A2 | Aminophenol derivatives | GLAXO GROUP LIMITED (GB) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178763-A1 | Method of Treating Anxious Major Depressive Disorder | DRD2, DRD4, HTR1D | HPGD 730/4885ALDH1A1 174/4885MAPT 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.